{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:11:30Z","timestamp":1784131890839,"version":"3.55.0"},"reference-count":15,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfus Med Hemother"],"abstract":"<jats:p>Introduction: The aim of this study was to investigate the clinical consequences of anti-D and non-anti-D antibodies undetected at screening in the first trimester for hemolytic disease of the fetus and newborn (HDFN). Methods: This prospective study (conducted from 2010 to 2024) included pregnant women with negative first-trimester antibody screening for red blood cell (RBC) antibodies but positive later in pregnancy for clinically significant antibodies anti-D and non-anti-D. We analyzed the incidence of antibodies, DAT of the newborn, and the treatment and outcomes of HDFN. Results: In study period, 61,200 pregnant women were tested, of which 11,000 were RhD\u2212. In 32 cases, anti-D antibodies were initially detected at the repeated screening (28th\/34th week of pregnancy or to 24 h post-delivery). All women have given birth to D+ child, of which 50% had a positive DAT. Four of them had early jaundice. In two cases, blood transfusion was required due to anemia. The incidence of anti-D antibody undetected at first trimester was 29\/10,000 in D\u2212 women. Anti-D antibody caused severe HDFN in 1.8\/10,000. Non-anti-D antibodies have been detected on repeated screening in seven cases, anti-c (N = 5), anti-E (N = 1), anti-C (N = 1). All seven neonates were antigen positive, three of which had positive DAT due to anti-c antibodies. The neonates with positive DAT had early jaundice and needed phototherapy, but there were no cases of severe HDFN in this group. Conclusion: First-trimester screening for RBC antibodies detected all cases of severe HDFN caused by non-anti-D antibodies out of 61,000 pregnant women tested.<\/jats:p>","DOI":"10.1159\/000552617","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:01:41Z","timestamp":1779379301000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["The Frequency of Severe Hemolytic Disease of the Fetus and Newborn Caused by Red Blood Cell Alloantibodies Undetected at the Antibodies Screening in the First Trimester: A Prospective Study"],"prefix":"10.1159","author":[{"given":"Slavica","family":"Dajak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anet Papazovska","family":"Cherepnalkovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Odak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12265"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.03006.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01625.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.13816"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-058859"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2015.129"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4103\/0974-2727.199627"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31817d453c"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.01.059"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/FM9.0000000000000279"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.12409"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13036"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13090"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012241"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15987"}],"container-title":["Transfusion Medicine and Hemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000552617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:00:50Z","timestamp":1784131250000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000552617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":15,"URL":"https:\/\/doi.org\/10.1159\/000552617","archive":["Portico"],"relation":{},"ISSN":["1660-3796","1660-3818"],"issn-type":[{"value":"1660-3796","type":"print"},{"value":"1660-3818","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}